Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487183 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL6181758 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL7425391 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL7556352 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL7559120 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL6183944 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL7565562 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL6184784 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL24113374 | 0.94 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL25362467 | 0.94 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-1948639-A2 | NOVEL CARBOCYCLIC FUSED CYCLIC AMINES | F. Hoffmann-la Roche AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054453-A2 | CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
| EP-0539192-B1 | HIV Protease inhibitors | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5502060-A | TREATMENT OF AIDS USING ENZUME INHIBITORS | MERCK & CO., INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1994026749-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1993008184-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539192-A1 | HIV Protease inhibitors | MERCK & CO. INC. (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5047400-A | Treatment of infection; antitumor agents | ADIR ET CIE (FR) | 1991-09-10 | — | — | US | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | HSD17B10 3186/4885SMN1; SMN2 3805/4885NR1H2 1469/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | HSD17B10 3186/4885SMN1; SMN2 3805/4885NR1H2 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.